EUVIMEDEUVIMED entdecken
Systematische Übersicht

Intravenous anakinra for the treatment of haemophagocytic lymphohistiocytosis/macrophage activation syndrome: A systematic review

James E G Charlesworth iD, Akhila Kavirayani

European Journal of Haematology · 2023

DOI: 10.1111/ejh.14029 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift European Journal of Haematology, 2023. Verfasst von James E G Charlesworth und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. Hauptthemen laut MEDLINE: Lymphohistiocytosis, Hemophagocytic, Macrophage Activation Syndrome, Sepsis, Rheumatic Diseases. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 83 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Haemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS) has a potentially high mortality rate. Anakinra, an interleukin‐1 receptor antagonist, is now recommended early in HLH/MAS, with intravenous (IV) use proposed in critically unwell patients. This systematic review establishes the literature relating to IV anakinra in secondary HLH/MAS (sHLH/MAS).

Methods

We screened Embase, PubMed, and Medline, including all reports of IV anakinra for HLH or MAS. We extracted age, HLH/MAS trigger, continuous infusion or bolus dosing, and survival.

Results

Twenty‐nine case reports/series identified 87 patients (median age 22 years, range 22 months to 84 years), all with sHLH. Amongst identifiable triggers, 43% were systemic infection, 33% rheumatological, 9% oncological. Children had predominantly a rheumatological trigger (48%), whilst adults were more commonly infection‐driven (50%). Overall, rheumatologically triggered disease showed greater survival (83.3%), particularly compared with oncological triggers (42.9%). Children had a greater survival, particularly under 10 years (83%, vs. adults, 63%).

Conclusions

Despite IV anakinra recipients likely to be critically unwell, this cohort had similar disease triggers and survival compared to large historical cohorts, and enhances awareness of age and trigger‐specific survival patterns. IV anakinra had a wide therapeutic dosing range and tolerability, regardless of trigger, demonstrating substantial utility in severe sHLH/MAS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphohistiocytosis, HemophagocyticMacrophage Activation SyndromeSepsisRheumatic DiseasesAdultChildHumansInfantInterleukin 1 Receptor Antagonist Protein

Stichwörter der Autor:innen

HLHIL-1 receptor antagonistIV anakinraMAScytokine stormhaemophagocytic lymphohistiocytosisintravenous anakinramacrophage activation syndrome

Substanzen

Interleukin 1 Receptor Antagonist Protein

Autor:innen und Institutionen

  • Department of Paediatrics, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Paediatric Rheumatology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

ORCID-Profile: James E G Charlesworth

Zitieren

APA

Charlesworth, J. E. G., & Kavirayani, A. (2023). Intravenous anakinra for the treatment of haemophagocytic lymphohistiocytosis/macrophage activation syndrome: A systematic review. European Journal of Haematology. https://doi.org/10.1111/ejh.14029

Vancouver

Charlesworth JEG, Kavirayani A. Intravenous anakinra for the treatment of haemophagocytic lymphohistiocytosis/macrophage activation syndrome: A systematic review. European Journal of Haematology. 2023. doi:10.1111/ejh.14029

BibTeX
@article{Charlesworth2023,
  author = {Charlesworth, James E G and Kavirayani, Akhila},
  title = {Intravenous anakinra for the treatment of haemophagocytic lymphohistiocytosis/macrophage activation syndrome: A systematic review},
  journal = {European Journal of Haematology},
  year = {2023},
  doi = {10.1111/ejh.14029}
}
Kostenlos starten →